Capturing Healthy Gut Bacteria Linked to High Fiber Diets

In Silico and in Vitro Targeting of Healthy Gut Bacteria With Fiber Degrading Metabolic Potential

Observational Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · NCT06166810

This study is trying to find out if a high-fiber diet helps healthy adults grow good gut bacteria that could improve their health.

Quick facts

Study typeObservational
Enrollment10 (estimated)
Ages20 Years to 50 Years
SexAll
SponsorInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement Academic / other
Locations1 site (Clermont-Ferrand)
Trial IDNCT06166810 on ClinicalTrials.gov

What this trial studies

This observational study aims to explore the relationship between a high-fiber diet and the intestinal microbiota by isolating and cultivating beneficial gut bacteria. It focuses on recruiting healthy adults aged 20 to 50 who consume a diet rich in fruits, vegetables, and cereals. The study seeks to identify new bacterial strains that could have health benefits, which have not yet been isolated or characterized. By understanding these bacteria, the research may contribute to future probiotic developments and dietary recommendations.

Who should consider this trial

Good fit: Ideal candidates for this study are healthy adults aged 20 to 50 with a BMI between 18.5 and 25 who consume a high-fiber diet.

Not a fit: Patients with known pathologies, recent antibiotic use, or those who consume excessive alcohol or processed foods may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to the identification of new beneficial gut bacteria that may improve health outcomes through dietary interventions.

How similar studies have performed: While many studies have explored the gut microbiota, this specific approach of isolating new beneficial bacteria from high-fiber diets is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Healthy adult subjects ;
* Age between 20 and 50 (limits included) ;
* BMI between 18.5 and 25 kg/m2 (excluding limits) ;
* Consumption of more than 5 portions of fruit and vegetables a day;
* Intake of at least 25g of dietary fibre per day;
* A varied diet with little processed food.

Exclusion Criteria:

* Antibiotics and/or transit modulators taken in the 3 months prior to sampling;
* Known pathologies;
* Current treatment;
* History of digestive surgery having an impact on the microbiota, deemed incompatible with the study (bariatric surgery);
* Consumption of food supplements based on protein preparations, probiotics or prebiotics;
* Smoking (even occasionally);
* Alcohol consumption \> 2 glasses (i.e. 20 g) per day;
* Intense sporting activity;
* Pregnant or breast-feeding women;
* Persons under legal protection (curatorship, guardianship, etc.);
* Volunteers taking part in another intervention study;
* Persons refusing to be registered on the French Ministry of Health's Fichier National des Volontaires Sains (National Register of Healthy Volunteers);
* Subject not affiliated to the social security system;
* Subject in a period of exclusion from a previous study or having received a total amount of compensation exceeding 6000 euros over the 12 consecutive months prior to the start of the trial (after verification in the Fichier des Volontaires pour la Recherche Biomédicale).

Where this trial is running

Clermont-Ferrand

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions General Population
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.